Early and sustained ctDNA clearance in early breast cancer treated with neoadjuvant HER2-targeted therapy tracks closely with pathologic complete response to treatment and 3-year outcomes.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer ...

Remco Evenepoel was named as the Belgian Sportsman of the Year for a fifth consecutive time on Sunday, with Eddy Merckx's ...

Remco Evenepoel has been voted Sportsman of the Year for the fifth time in Belgium. The rider, who this winter made the ...

JPMorgan Equity Premium Income ETF delivers consistent monthly income with a 7-8% yield, though it lags the broader market's ...

Spain’s Central Veterinary Laboratory in Madrid has confirmed three more wild boars have tested positive for African swine ...

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs ...

The study presents convincing quantitative evidence, supported by appropriate negative controls, for the presence of low-abundance glycine receptors (GlyRs) within inhibitory synapses in telencephalic ...

See related editorial at Key points In 2002, the G8 summit in Kananaskis, Alberta, launched the G8 Africa Action Plan,[1][2] which identified HIV/AIDS as a central threat to human development and ...

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.